- Novel drugs for ATTR amyloidosis
- Organ transplant in systemic amyloidosis
- Practical approach to mutant TTR carriers
- Prevention and management of drug-related toxicities in systemic amyloidosis
- Imaging techniques in amyloidosis
Treatment of Patients with AL Amyloidosis non-eligible for ASCT with emphasis on Novel Agents
Overview (8:00-8:20)
Question and Answer Panel (8:20-9:15)
Panelists:
- Best initial therapy for fit patients
- Best inicial therapy for unfit patients
- When to start therapy at relapse or progression
- Treatment at first relapse
- Treatment at later relapses or refractory disease
- Best novel emerging agents
Heredinary Transthyretin Amyloidosis
- Mechanisms of organ damage in ATTR amyloidosis
- RNA interference for gene expression control in ATTR amyloidosis
- Hereditary ATTR amyloidosis: role of RNA interference therapy
Taylor&Francis (managing editor of Amyloid)
Hereditary ATTR Amyloidosis: Clinical Features and Follow-up
- Clinical features of polyneuropathy in hereditary amyloidosis
- Red-flags for early diagnosis in hereditary amyloidosis
- The global prevalence of ATTR amyloidosis
- Unusual manifestations in ATTR amyloidosis
- Follow-up, polyneuropathy detection, de novo manifestations and treatment after domino liver transplantation
 Other Forms of Amyloidosis
- Localized amyloidosis
- AA amyloidosis associated with autoinflamatory diseases
- Systemic wild-type ATTR amyloidosis
- Hereditary non-transthyretin amyloidosis
- CNS and ocular involvement in hereditary amyloidosis
- LECT2-associated renal amyloidosis